How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Infectious Disease Archives

Safety and Immunogenicity Results for GS-2829 and GS-6779

Another Vaccine-Preventable Disease Seeing a Major Resurgence

Global Study Reports 98.9% SVR with SOF/VEL in Over 7,000 Hepatitis C Patients

Greater Incidence of Antimicrobial Resistant Infections in Cancer Outpatients

Colonoscopic Administration of Rebyota Shows Effectiveness for Preventing Recurrent C difficile Infection

When Will the Measles Outbreak End?

RSV Vaccine Effectiveness and Safety in Older Adults: Real-World Case-Control Study Findings

FDA and CDC Recommend Pause on Chikungunya Vaccine IXCHIQ for Adults 65 and Older

Microbiota-Based Therapy Improves Mental Quality of Life in rCDI Trial

Vir Biotechnology Announces Results of its Potential Hepatitis B Cure Combination Therapy

Schedule an Appointment

Quick Links

Patient Forms

Contact Us